‘Lab-on-a-Chip’ microfluidics technology may cut costs of lab tests for diseases and disorders
September 14, 2015
Rutgers engineers have developed a breakthrough microfluidics device that can significantly reduce the cost of sophisticated lab tests while using 90 percent less sample fluid than needed in conventional tests.
It uses miniaturized channels and valves to replace “benchtop” assays — tests that require large samples of blood or other fluids and expensive chemicals that lab technicians manually mix in trays of tubes or plastic plates with cup-like depressions.
The device also requires only one-tenth of the chemicals used in a conventional multiplex immunoassay, which can cost as much as $1500, and it automates much of the skilled labor involved in performing tests, according to Mehdi Ghodbane, who earned his doctorate in biomedical engineering at Rutgers and now works in biopharmaceutical research and development at GlaxoSmithKline.
Ghodbane and six Rutgers researchers recently published their results in the Royal Society of Chemistry’s journal, Lab on a Chip.
“The results are as sensitive and accurate as the standard benchtop assay,’’ said Martin Yarmush, the Paul and Mary Monroe Chair and Distinguished Professor of biomedical engineering at Rutgers and Ghodbane’s adviser.
Until now, animal research on central nervous system disorders, such as spinal cord injury and Parkinson’s disease, has been limited because researchers could not extract sufficient cerebrospinal fluid to perform conventional assays. “With our technology, researchers will be able to perform large-scale controlled studies with comparable accuracy to conventional assays,” Yarmush said.
The discovery could also lead to more comprehensive research on autoimmune joint diseases such as rheumatoid arthritis through animal studies. As with spinal fluid, the amount of joint fluid, or synovial fluid, researchers are able to collect from lab animals is minuscule.
The Rutgers team has combined several capabilities for the first time in the device they’ve dubbed “ELISA-on-a-chip” (for enzyme-linked immunosorbent assay). A single device analyzes 32 samples at once and can measure widely varying concentrations of as many as six proteins in a sample.
While there has been a lot of research in lab-on-a-chip technology covered on KurzweilAI, the new device is unique in using commercially available reagents, which allows the analytes of interest to be easily changed and can measure 6 proteins in 32 samples simultaneously using only 4.2 microliters of sample volume, the researchers note in the paper.
The researchers are exploring the commercial potential of their technology. The research was partially funded by the National Institute of Health grants, the National Institute of Health Rutgers Biotechnology Training Program, the National Science Foundation Integrated Science and Engineering of Stem Cells Program, The New Jersey Commission on Brain Injury Research, and Corning Inc.
Abstract of Development and validation of a microfluidic immunoassay capable of multiplexing parallel samples in microliter volumes
Immunoassays are widely utilized due to their ability to quantify a vast assortment of biomolecules relevant to biological research and clinical diagnostics. Recently, immunoassay capabilities have been improved by the development of multiplex assays that simultaneously measure multiple analytes in a single sample. However, these assays are hindered by high costs of reagents and relatively large sample requirements. For example, in vitro screening systems currently dedicate individual wells to each time point of interest and this limitation is amplified in screening studies when the investigation of many experimental conditions is necessary; resulting in large volumes for analysis, a correspondingly high cost and a limited temporal experimental design. Microfluidics based immunoassays have been developed in order to overcome these drawbacks. Together, previous studies have demonstrated on-chip assays with either a large dynamic range, high performance sensitivity, and/or the ability to process samples in parallel on a single chip. In this report, we develop a multiplex immunoassay possessing all of these parallel characteristics using commercially available reagents, which allows the analytes of interest to be easily changed. The device presented can measure 6 proteins in 32 samples simultaneously using only 4.2 μL of sample volume. High quality standard curves are generated for all 6 analytes included in the analysis, and spiked samples are quantified throughout the working range of the assay. In addition, we demonstrate a strong correlation (R2 = 0.8999) between in vitro supernatant measurements using our device and those obtained from a bench-top multiplex immunoassay. Finally, we describe cytokine secretion in an in vitro inflammatory hippocampus culture system, establishing proof-of-concept of the ability to use this platform as an in vitro screening tool. The low-volume, multiplexing abilities of the microdevice described in this report could be broadly applied to numerous situations where sample volumes and costs are limiting.
- Mehdi Ghodbane, Elizabeth C. Stucky, Tim J. Maguire, Rene S. Schloss, David I. Shreiber, Jeffrey D. Zahna and Martin L. Yarmush. Development and validation of a microfluidic immunoassay capable of multiplexing parallel samples in microliter volumes. Lab Chip, 2015,15, 3211-3221; DOI: 10.1039/C5LC00398A